Washington University

Randall John Bateman

David Michael Holtzman

Nicolas Barthelemy

Eric McDade

Chihiro Sato

Kwasi Mawuenyega

Tim Miller

Kwasi G Mawuenyega

David M Holtzman

The present disclosure provides methods for blood-based examination useful to identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein.

Blood-based methods for determining Aβ amyloidosis

The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

Methods of treating based on site-specific tau phosphorylation

The invention relates to in vitro methods for measuring the in vivo metabolism of tau in a subject.

Tau kinetic measurements

The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for neurological and neurodegenerative diseases and disorders, such as Alzheimer's Disease, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.

Growing community of inventors

Grover, MO, United States of America

Randall John Bateman